These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

307 related articles for article (PubMed ID: 27218790)

  • 81. A phase II, multicenter, open-label, 3-cohort trial evaluating the efficacy and safety of vismodegib in operable basal cell carcinoma.
    Sofen H; Gross KG; Goldberg LH; Sharata H; Hamilton TK; Egbert B; Lyons B; Hou J; Caro I
    J Am Acad Dermatol; 2015 Jul; 73(1):99-105.e1. PubMed ID: 25913533
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib.
    Sternfeld A; Rosenwasser-Weiss S; Ben-Yehuda G; Shefer HK; Friedman-Gohas M; Yassur I; Tauber G; Bejar J; Olshinka A; Vardizer Y; Ad El D; Goldenberg-Cohen N
    Sci Rep; 2020 Jan; 10(1):1244. PubMed ID: 31988301
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Systemic treatments for basal cell carcinoma (BCC): the advent of dermato-oncology in BCC.
    Ali FR; Lear JT
    Br J Dermatol; 2013 Jul; 169(1):53-7. PubMed ID: 23488543
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Eight years of experience with vismodegib for advanced and multiple basal cell carcinoma patients in the Netherlands: a retrospective cohort study.
    Verkouteren BJA; Wakkee M; Reyners AKL; Nelemans P; Aarts MJB; Rácz E; Terra JB; Devriese LA; Alers RJ; Kapiteijn E; van Doorn R; Bekkenk MW; Reinders MGHC; Mosterd K
    Br J Cancer; 2021 Mar; 124(7):1199-1206. PubMed ID: 33462360
    [TBL] [Abstract][Full Text] [Related]  

  • 85. U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma.
    Axelson M; Liu K; Jiang X; He K; Wang J; Zhao H; Kufrin D; Palmby T; Dong Z; Russell AM; Miksinski S; Keegan P; Pazdur R
    Clin Cancer Res; 2013 May; 19(9):2289-93. PubMed ID: 23515405
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Hedgehog Pathway Inhibition.
    Sekulic A; Von Hoff D
    Cell; 2016 Feb; 164(5):831. PubMed ID: 26919418
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Reflectance confocal microscopy identification of subclinical basal cell carcinomas during and after vismodegib treatment.
    Couzan C; Cinotti E; Labeille B; Vercherin P; Rubegni P; Cambazard F; Perrot JL
    J Eur Acad Dermatol Venereol; 2018 May; 32(5):763-767. PubMed ID: 29055164
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Clinical benefit assessment of vismodegib therapy in patients with advanced basal cell carcinoma.
    Dreno B; Basset-Seguin N; Caro I; Yue H; Schadendorf D
    Oncologist; 2014 Aug; 19(8):790-6. PubMed ID: 25001266
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Predictive factors of response to vismodegib: a French study of 61 patients with multiple or locally advanced basal cell carcinoma.
    Juzot C; Isvy-Joubert A; Khammari A; Knol AC; Nguyen JM; Dreno B
    Eur J Dermatol; 2022 May; 32(3):401-407. PubMed ID: 36065537
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Induction Hedgehog pathway inhibition followed by combined-modality radiotherapy for basal cell carcinoma.
    Raleigh DR; Algazi A; Arron ST; Neuhaus IM; Yom SS
    Br J Dermatol; 2015 Aug; 173(2):544-6. PubMed ID: 25702621
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Follow-Up of Patients With Complete Remission of Locally Advanced Basal Cell Carcinoma After Vismodegib Discontinuation: A Multicenter French Study of 116 Patients.
    Herms F; Lambert J; Grob JJ; Haudebourg L; Bagot M; Dalac S; Dutriaux C; Guillot B; Jeudy G; Mateus C; Monestier S; Mortier L; Poulalhon N; Prey S; Robert C; Vabres P; Lebbe C; Meyer N; Basset-Seguin N
    J Clin Oncol; 2019 Dec; 37(34):3275-3282. PubMed ID: 31609670
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Vismodegib for locally advanced basal cell carcinoma in a heart transplant patient.
    Cusack CA; Nijhawan R; Miller B; Henien M; Malat G; Doyle A; Abdelmalek M
    JAMA Dermatol; 2015 Jan; 151(1):70-2. PubMed ID: 25337679
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Vismodegib: a promising drug in the treatment of basal cell carcinomas.
    Dirix L; Rutten A
    Future Oncol; 2012 Aug; 8(8):915-28. PubMed ID: 22894666
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Predictive Factors of Non-Response to Vismodegib in Locally Advanced Basal-Cell Carcinoma.
    Marescassier H; Dousset L; Beylot-Barry M; Célérier P; Vaillant L; Bedane C; Leclère F; Wierzbicka-Hainaut E; Masson Regnault M
    Dermatology; 2021; 237(6):1023-1028. PubMed ID: 33472195
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Managing adverse events associated with vismodegib in the treatment of basal cell carcinoma.
    Fife K; Herd R; Lalondrelle S; Plummer R; Strong A; Jones S; Lear JT
    Future Oncol; 2017 Jan; 13(2):175-184. PubMed ID: 27640448
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Advanced basal cell carcinoma treated with vismodegib: impact on the lives of patients and their families.
    Villani A; Cappello M; Costa C; Fabbrocini G; Scalvenzi M
    Clin Exp Dermatol; 2020 Dec; 45(8):1044-1046. PubMed ID: 32415864
    [TBL] [Abstract][Full Text] [Related]  

  • 97. [Vismodegib for basal cell carcinoma: targeted therapy in case of locally advanced or metastasised disease].
    Reinders MG; Terra JB; Reyners AK; Aarts MJ; de Haas ER; Mosterd K
    Ned Tijdschr Geneeskd; 2016; 160():D187. PubMed ID: 28000572
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Real-World Experience of Vismodegib in Advanced Basal Cell Carcinoma at a Canadian Cancer Center.
    Tong J; Mitchell B; Roth K; Logan D; Ernst S
    J Cutan Med Surg; 2022; 26(2):143-148. PubMed ID: 34663118
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Fast-growing cutaneous squamous cell carcinoma in a patient treated with vismodegib.
    Poulalhon N; Dalle S; Balme B; Thomas L
    Dermatology; 2015; 230(2):101-4. PubMed ID: 25633488
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Metastatic spinal cord compression from basal cell carcinoma of the skin treated with surgical decompression and vismodegib: case report and review of Hedgehog signalling pathway inhibition in advanced basal cell carcinoma.
    McGrane J; Carswell S; Talbot T
    Clin Exp Dermatol; 2017 Jan; 42(1):80-83. PubMed ID: 27905158
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.